§ Venture Capital · Shanghai, China

New Alliance Capital

New Alliance Capital is an investment firm.

Active

Updated:Apr 20, 2026

Financial History

1 people

Key people at New Alliance Capital.

Liefeng Qu

Who founded New Alliance Capital?

New Alliance Capital was founded in 2008 by Liefeng Qu (Founder and partner).

Loading organizations...

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Feb 2, 2026	Aerofugia	$144.0M Series C	CITIC Securities	CAS Star, Green Pine Capital Partners, Luminous Ventures (former Lightspeed China Partners), PAN LIN Capital, Panorama Capital, Vertex Ventures China, Yunsheng Capital
Aug 25, 2025	Arnatar Therapeutics	$52.0M Series A	3E Bioventures Capital, Eight Roads Ventures	Chuanhua Capital, F Prime Capital, Gaorong Capital, Hongsheng Capital, Yijing Capital
Jan 5, 2024	Elite Technology	$14.0M Other Equity	—	—
Sep 21, 2023	LYNK Pharmaceuticals	$44.1M Series C	China Grand Prosperity Investment	Lilly Asia Ventures
Jun 12, 2023	Eccogene	$25.2M Series B	NEW Alliance Capital, Zhangjiang Healthcare Venture Capital	Delos Capital, Rockbleu Capital, Yufu Investment
Aug 29, 2021	LYNK Pharmaceuticals	$50.0M Series B	Lilly Asia Ventures	Heda Ventures, Legend Capital, MED Fine Capital
Aug 17, 2021	Meditrust	$308.7M Series C	Boyu Capital, Janchor Partners	Aihc Capital, Bank OF China Group Investment, China Everbright, China Renaissance, CICC Capital, Lake Bleu Capital, Lilly Asia Ventures, Marathon Venture Partners, Shanghai Biopharmaceutical Fund, Sinovation Ventures
Mar 22, 2021	Tavotek Biotherapeutics	$20.0M Series A	—	CTS Capital, Lanhu Capital, Oriza Holdings
Mar 26, 2019	Innoviz Technologies	$132.0M Series C	—	China Merchants Capital, Harel Insurance Investments & Financial Services, Phoenix Insurance Company, Shenzhen Capital Group
Apr 14, 2018	Guanan Information	$20.7M Series B	—	Zhangjiang Group

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Feb 2, 2026	Aerofugia	$144.0M Series C	CITIC Securities	CAS Star, Green Pine Capital Partners, Luminous Ventures (former Lightspeed China Partners), PAN LIN Capital, Panorama Capital, Vertex Ventures China, Yunsheng Capital
Aug 25, 2025	Arnatar Therapeutics	$52.0M Series A	3E Bioventures Capital, Eight Roads Ventures	Chuanhua Capital, F Prime Capital, Gaorong Capital, Hongsheng Capital, Yijing Capital
Jan 5, 2024	Elite Technology	$14.0M Other Equity	—	—
Sep 21, 2023	LYNK Pharmaceuticals	$44.1M Series C	China Grand Prosperity Investment	Lilly Asia Ventures
Jun 12, 2023	Eccogene	$25.2M Series B	NEW Alliance Capital, Zhangjiang Healthcare Venture Capital	Delos Capital, Rockbleu Capital, Yufu Investment
Aug 29, 2021	LYNK Pharmaceuticals	$50.0M Series B	Lilly Asia Ventures	Heda Ventures, Legend Capital, MED Fine Capital
Aug 17, 2021	Meditrust	$308.7M Series C	Boyu Capital, Janchor Partners	Aihc Capital, Bank OF China Group Investment, China Everbright, China Renaissance, CICC Capital, Lake Bleu Capital, Lilly Asia Ventures, Marathon Venture Partners, Shanghai Biopharmaceutical Fund, Sinovation Ventures
Mar 22, 2021	Tavotek Biotherapeutics	$20.0M Series A	—	CTS Capital, Lanhu Capital, Oriza Holdings
Mar 26, 2019	Innoviz Technologies	$132.0M Series C	—	China Merchants Capital, Harel Insurance Investments & Financial Services, Phoenix Insurance Company, Shenzhen Capital Group
Apr 14, 2018	Guanan Information	$20.7M Series B	—	Zhangjiang Group